An open trial of transdermal nicotine replacement therapy for smoking cessation among alcohol- and drug-dependent inpatients

Andrew J. Saxon, Robert McGuffin, Roger (Dale) Walker

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

An open trial of transdermal nicotine replacement for smoking cessation was conducted. Over a 7-month period, all patients admitted to the inpatient alcohol and drug treatment unit of the Seattle Veterans Affairs Medical Center (n = 207) were offered the opportunity to participate in an open trial of transdermal nicotine replacement for smoking cessation. Forty-nine (23.7%) elected to attempt cessation with transdermal nicotine during their inpatient treatment episodes. These subjects received no psychosocial treatments directed specifically at smoking cessation. They smoked a mean of 28.5 (SD = 16.4) cigarettes per day and obtained a mean score of 8.3 (SD = 1.9) on the Fagerstrom Test for Nicotine Dependence. Subjects remained on transdermal nicotine an average of 18.8 (SD = 8.2) days with desire to resume smoking the major reason for discontinuation. Seven subjects (14.3%) self-reported tobacco abstinence at 21 days, and 5 (10.2%) self-reported abstinence as outpatients at 6 weeks. These results show that a substantial proportion of alcohol- and drug-dependent patients entering inpatient treatment are willing to attempt alcohol and illicit drug cessation and tobacco cessation simultaneously and that transdermal nicotine holds promise as a treatment modality in this population.

Original languageEnglish (US)
Pages (from-to)333-337
Number of pages5
JournalJournal of Substance Abuse Treatment
Volume14
Issue number4
DOIs
StatePublished - Jul 1997
Externally publishedYes

Fingerprint

Smoking Cessation
Nicotine
Inpatients
Alcohols
Pharmaceutical Preparations
Tobacco Use Cessation
Therapeutics
Tobacco Use Disorder
Street Drugs
Veterans
Tobacco Products
Tobacco
Outpatients
Smoking
Population

Keywords

  • Alcohol dependence
  • Drug dependence
  • Nicotine dependence
  • Smoking cessation
  • Transdermal nicotine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

An open trial of transdermal nicotine replacement therapy for smoking cessation among alcohol- and drug-dependent inpatients. / Saxon, Andrew J.; McGuffin, Robert; Walker, Roger (Dale).

In: Journal of Substance Abuse Treatment, Vol. 14, No. 4, 07.1997, p. 333-337.

Research output: Contribution to journalArticle

@article{49df901e902243bd86e59f2e72cfa688,
title = "An open trial of transdermal nicotine replacement therapy for smoking cessation among alcohol- and drug-dependent inpatients",
abstract = "An open trial of transdermal nicotine replacement for smoking cessation was conducted. Over a 7-month period, all patients admitted to the inpatient alcohol and drug treatment unit of the Seattle Veterans Affairs Medical Center (n = 207) were offered the opportunity to participate in an open trial of transdermal nicotine replacement for smoking cessation. Forty-nine (23.7{\%}) elected to attempt cessation with transdermal nicotine during their inpatient treatment episodes. These subjects received no psychosocial treatments directed specifically at smoking cessation. They smoked a mean of 28.5 (SD = 16.4) cigarettes per day and obtained a mean score of 8.3 (SD = 1.9) on the Fagerstrom Test for Nicotine Dependence. Subjects remained on transdermal nicotine an average of 18.8 (SD = 8.2) days with desire to resume smoking the major reason for discontinuation. Seven subjects (14.3{\%}) self-reported tobacco abstinence at 21 days, and 5 (10.2{\%}) self-reported abstinence as outpatients at 6 weeks. These results show that a substantial proportion of alcohol- and drug-dependent patients entering inpatient treatment are willing to attempt alcohol and illicit drug cessation and tobacco cessation simultaneously and that transdermal nicotine holds promise as a treatment modality in this population.",
keywords = "Alcohol dependence, Drug dependence, Nicotine dependence, Smoking cessation, Transdermal nicotine",
author = "Saxon, {Andrew J.} and Robert McGuffin and Walker, {Roger (Dale)}",
year = "1997",
month = "7",
doi = "10.1016/S0740-5472(97)00031-7",
language = "English (US)",
volume = "14",
pages = "333--337",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - An open trial of transdermal nicotine replacement therapy for smoking cessation among alcohol- and drug-dependent inpatients

AU - Saxon, Andrew J.

AU - McGuffin, Robert

AU - Walker, Roger (Dale)

PY - 1997/7

Y1 - 1997/7

N2 - An open trial of transdermal nicotine replacement for smoking cessation was conducted. Over a 7-month period, all patients admitted to the inpatient alcohol and drug treatment unit of the Seattle Veterans Affairs Medical Center (n = 207) were offered the opportunity to participate in an open trial of transdermal nicotine replacement for smoking cessation. Forty-nine (23.7%) elected to attempt cessation with transdermal nicotine during their inpatient treatment episodes. These subjects received no psychosocial treatments directed specifically at smoking cessation. They smoked a mean of 28.5 (SD = 16.4) cigarettes per day and obtained a mean score of 8.3 (SD = 1.9) on the Fagerstrom Test for Nicotine Dependence. Subjects remained on transdermal nicotine an average of 18.8 (SD = 8.2) days with desire to resume smoking the major reason for discontinuation. Seven subjects (14.3%) self-reported tobacco abstinence at 21 days, and 5 (10.2%) self-reported abstinence as outpatients at 6 weeks. These results show that a substantial proportion of alcohol- and drug-dependent patients entering inpatient treatment are willing to attempt alcohol and illicit drug cessation and tobacco cessation simultaneously and that transdermal nicotine holds promise as a treatment modality in this population.

AB - An open trial of transdermal nicotine replacement for smoking cessation was conducted. Over a 7-month period, all patients admitted to the inpatient alcohol and drug treatment unit of the Seattle Veterans Affairs Medical Center (n = 207) were offered the opportunity to participate in an open trial of transdermal nicotine replacement for smoking cessation. Forty-nine (23.7%) elected to attempt cessation with transdermal nicotine during their inpatient treatment episodes. These subjects received no psychosocial treatments directed specifically at smoking cessation. They smoked a mean of 28.5 (SD = 16.4) cigarettes per day and obtained a mean score of 8.3 (SD = 1.9) on the Fagerstrom Test for Nicotine Dependence. Subjects remained on transdermal nicotine an average of 18.8 (SD = 8.2) days with desire to resume smoking the major reason for discontinuation. Seven subjects (14.3%) self-reported tobacco abstinence at 21 days, and 5 (10.2%) self-reported abstinence as outpatients at 6 weeks. These results show that a substantial proportion of alcohol- and drug-dependent patients entering inpatient treatment are willing to attempt alcohol and illicit drug cessation and tobacco cessation simultaneously and that transdermal nicotine holds promise as a treatment modality in this population.

KW - Alcohol dependence

KW - Drug dependence

KW - Nicotine dependence

KW - Smoking cessation

KW - Transdermal nicotine

UR - http://www.scopus.com/inward/record.url?scp=0030687664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030687664&partnerID=8YFLogxK

U2 - 10.1016/S0740-5472(97)00031-7

DO - 10.1016/S0740-5472(97)00031-7

M3 - Article

C2 - 9368209

AN - SCOPUS:0030687664

VL - 14

SP - 333

EP - 337

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 4

ER -